Literature DB >> 2481599

Changes in serum levels of hepatitis B virus markers after interferon treatment.

H Ikeda1, K Matsuura, T Tsuji.   

Abstract

The effect of interferon (IFN) treatment on serum levels of pre-S antigens [pre-S(1) antigen, pre-S(2) antigen, polymerized human serum albumin receptor (pAR)] which are coded by the pre-S region of hepatitis B virus DNA (HBV-DNA), and HBV-markers was analyzed in 23 patients with chronic hepatitis B. One year after IFN treatment, 4 patients (Group C) became HBeAg negative. Six patients (Group B) transiently became HBeAg-negative, but reverted to HBeAg positive. Thirteen patients (Group A) remained HBeAg positive. All of the patients remained HBsAg-positive. Initiation of IFN treatment was rapidly followed by reduction or loss of DNA-P in the serum whether the patients became HBeAg negative or remained positive, and whether serum transaminase (S-GPT) levels became normal or not after IFN treatment. Group C patients, in whom pre-S antigens decreased rapidly during IFN treatment and disappeared before S-GPT levels normalized, became HBeAg negative one year after IFN treatment. Anti-pAR was detected in three out of these 4 patients. In contrast, Group A and Group B patients, in whom pre-S antigens decreased slowly during IFN treatment and did not disappear in spite of those patients being transiently negative for HBeAg and DNA-P, remained HBeAg positive with elevated S-GPT levels one year after IFN treatment. Anti-pAR was almost undetectable. These results suggest that testing for pre-S antigens is more useful for determining the prognosis of patients with chronic hepatitis B treated with IFN than testing for HBsAg, HBeAg and DNA-P.

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2481599     DOI: 10.1007/bf02774163

Source DB:  PubMed          Journal:  Gastroenterol Jpn        ISSN: 0435-1339


  24 in total

1.  Antibody to the receptor for polymerized human serum albumin in acute and persistent infection with hepatitis B virus.

Authors:  H Okamoto; S Usuda; M Imai; K Tachibana; E Tanaka; T Kumakura; M Itabashi; E Takai; F Tsuda; T Nakamura
Journal:  Hepatology       Date:  1986 May-Jun       Impact factor: 17.425

2.  Hemagglutination assay of polypeptide coded by the pre-S region of hepatitis B virus DNA with monoclonal antibody: correlation of pre-S polypeptide with the receptor for polymerized human serum albumin in serums containing hepatitis B antigens.

Authors:  H Okamoto; M Imai; S Usuda; E Tanaka; K Tachibana; S Mishiro; A Machida; T Nakamura; Y Miyakawa; M Mayumi
Journal:  J Immunol       Date:  1985-02       Impact factor: 5.422

3.  Solid-phase enzyme-immunoassay for detection of hepatitis B surface antigen.

Authors:  G Wolters; L Kuijpers; J Kacaki; A Schuurs
Journal:  J Clin Pathol       Date:  1976-10       Impact factor: 3.411

Review 4.  Interferons with special emphasis on the immune system.

Authors:  R M Friedman; S N Vogel
Journal:  Adv Immunol       Date:  1983       Impact factor: 3.543

5.  Large surface proteins of hepatitis B virus containing the pre-s sequence.

Authors:  K H Heermann; U Goldmann; W Schwartz; T Seyffarth; H Baumgarten; W H Gerlich
Journal:  J Virol       Date:  1984-11       Impact factor: 5.103

6.  A receptor for polymerized human and chimpanzee albumins on hepatitis B virus particles co-occurring with HBeAg.

Authors:  M Imai; Y Yanase; T Nojiri; Y Miyakawa; M Mayumi
Journal:  Gastroenterology       Date:  1979-02       Impact factor: 22.682

7.  A polypeptide containing 55 amino acid residues coded by the pre-S region of hepatitis B virus deoxyribonucleic acid bears the receptor for polymerized human as well as chimpanzee albumins.

Authors:  A Machida; S Kishimoto; H Ohnuma; K Baba; Y Ito; H Miyamoto; G Funatsu; K Oda; S Usuda; S Togami
Journal:  Gastroenterology       Date:  1984-05       Impact factor: 22.682

8.  Analysis of liver disease, nuclear HBcAg, viral replication, and hepatitis B virus DNA in liver and serum of HBeAg Vs. anti-HBe positive carriers of hepatitis B virus.

Authors:  S J Hadziyannis; H M Lieberman; G G Karvountzis; D A Shafritz
Journal:  Hepatology       Date:  1983 Sep-Oct       Impact factor: 17.425

9.  Antiviral treatment of chronic hepatitis B virus infection. I. Changes in viral markers with interferon combined with adenine arabinoside.

Authors:  G H Scullard; R B Pollard; J L Smith; S L Sacks; P B Gregory; W S Robinson; T C Merigan
Journal:  J Infect Dis       Date:  1981-06       Impact factor: 5.226

10.  Prospective study of cellular immunity to hepatitis-B-virus antigens from the early incubation phase of acute hepatitis B.

Authors:  S Vento; E G Rondanelli; S Ranieri; C J O'Brien; R Williams; A L Eddleston
Journal:  Lancet       Date:  1987-07-18       Impact factor: 79.321

View more
  2 in total

1.  Changes of pre-S1 and pre-S2 antigens in sera of patients with hepatitis B virus infection.

Authors:  Y Iwasaki; K Matsuura; T Tsuji
Journal:  Gastroenterol Jpn       Date:  1990-08

2.  Clinical significance of low or negative titer of antibody to hepatitis B core antigen during the course of chronic hepatitis B virus infection in adolescents.

Authors:  K Matsuura; K Tobe; Y Iwasaki; H Ikeda; K Takahashi; T Tsuji
Journal:  Gastroenterol Jpn       Date:  1993-02
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.